Abstract {P}1-12-03: {Short} term quality of life with epirubicin-fluorouracil-cyclophosphamid ({FEC}) and sequential epirubicin/cyclophosphamid-docetaxel ({EC}-{DOC}) chemotherapy in patients with primary breast cancer – {Results} from the prospective multi-center randomized {Adebar} trial

Research output: Contribution to journal › Meeting abstract › Contributed

Contributors

  • L Schwentner - (Author)
  • N Harbeck - (Author)
  • S Singer - (Author)
  • M Eichler - , University Cancer Centre (Author)
  • B Rack - (Author)
  • H Forstbauer - (Author)
  • A Wischnik - (Author)
  • C Scholz - (Author)
  • V Fink - (Author)
  • J Huober - (Author)
  • T Friedl - (Author)
  • T Weissenbacher - (Author)
  • K Härtl - (Author)
  • M Kiechle - (Author)
  • W Janni - (Author)

Details

Original languageEnglish
Article numberP1-12-03
JournalCancer research
Volume76
Issue numberSuppl 4
Publication statusPublished - 2016
Peer-reviewedNo

External IDs

WOS 000375622400003

Keywords

Sustainable Development Goals